RxDoctor Payments Data

Jonathan Insel

Endocrinology, Diabetes & Metabolism · Tucson, AZNPI 1053350728

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 455 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,374 and has fallen 78.3% since, to $515 in 2023.

$7,477in general payments, 2019–2025

Across 455 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$994
  • Novo Nordisk$807
  • Abbott$545
  • Corcept Therapeutics$460
  • Mannkind Corporation$443
  • Sanofi-aventis U.S. LLC$407
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$7,43399%
  • Education$441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,477 in reported general payments places this provider in the 70th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$19,631
Soliqua 100-33Insulin Glargine/Lixisenatide11$17,299
JardianceEmpagliflozin14$10,821
SynthroidLevothyroxine Sodium38$4,821
HumalogInsulin Lispro13$2,959
Levothyroxine Sodium126$1,452
Metformin Hcl ErMetformin Hcl30$415
Rosuvastatin Calcium34$285
Ezetimibe14$243
Amlodipine Besylate25$223
Methimazole18$204
Simvastatin13$192
Losartan Potassium18$181
Spironolactone15$170
Lisinopril15$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$807$19,63117 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$407$17,29911 claims
Boehringer IngelheimJardiance$366$10,82114 claims
AbbVieSynthroid$331$4,82138 claims
Lilly USA, LLCHumalog$384$2,95913 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$84$1,452126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

Other endocrinology, diabetes & metabolism in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →